Form 4: Maze Therapeutics CEO Executes Planned Stock Sale
Statement of Changes in Beneficial Ownership
CEO Jason V. Coloma sold 1,938 shares of Maze Therapeutics common stock via a pre-arranged Rule 10b5-1 trading plan.
Summary
- CEO Jason V. Coloma sold a total of 1,938 shares of Maze Therapeutics common stock on May 15, 2026.
- The shares were sold at a price of $26.00 per share.
- The transactions were executed through two trusts: 1,822 shares from the Coloma Family Trust and 116 shares from The Coloma 2021 Irrevocable Trust.
- The filing includes a correction to previous ownership reporting, clarifying that these holdings are held in trust rather than directly by the CEO.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was planned in advance to avoid concerns regarding insider trading.
Negatives
- The filing reveals a previous reporting error regarding the direct versus indirect ownership of shares, which has now been corrected.
Risks
- Future sales by the CEO could impact market sentiment regarding the company's valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biotechnology sector and generally does not signal a lack of confidence in company fundamentals.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining regulatory compliance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Correction | Correction of ownership attribution for shares held in trusts. | 05/18/2026 | Minor administrative correction with no impact on company operations. |
Related Party Transactions
- The reporting person serves as co-trustee for the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and limited in scope.
Next Steps
- Continued monitoring of future Form 4 filings for additional transactions under the established trading plan.
Key Dates
| Date | Description |
|---|---|
| 02/06/2026 | Date the Rule 10b5-1 trading plan was adopted. |
| 05/15/2026 | Date of the stock sale transactions. |
| 05/18/2026 | Date the Form 4 was filed. |
Keywords
Maze Therapeutics, MAZE, Insider Trading, Form 4, Rule 10b5-1, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.